Gallagher Katherine E, Howard Natasha, Kabakama Severin, Mounier-Jack Sandra, Griffiths Ulla K, Feletto Marta, Burchett Helen E D, LaMontagne D Scott, Watson-Jones Deborah
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.
PLoS One. 2017 Jun 2;12(6):e0177773. doi: 10.1371/journal.pone.0177773. eCollection 2017.
To synthesise lessons learnt and determinants of success from human papillomavirus (HPV) vaccine demonstration projects and national programmes in low- and middle-income countries (LAMICs).
Interviews were conducted with 56 key informants. A systematic literature review identified 2936 abstracts from five databases; after screening 61 full texts were included. Unpublished literature, including evaluation reports, was solicited from country representatives; 188 documents were received. A data extraction tool and interview topic guide outlining key areas of inquiry were informed by World Health Organization guidelines for new vaccine introduction. Results were synthesised thematically.
Data were analysed from 12 national programmes and 66 demonstration projects in 46 countries. Among demonstration projects, 30 were supported by the GARDASIL® Access Program, 20 by Gavi, four by PATH and 12 by other means. School-based vaccine delivery supplemented with health facility-based delivery for out-of-school girls attained high coverage. There were limited data on facility-only strategies and little evaluation of strategies to reach out-of-school girls. Early engagement of teachers as partners in social mobilisation, consent, vaccination day coordination, follow-up of non-completers and adverse events was considered invaluable. Micro-planning using school/ facility registers most effectively enumerated target populations; other estimates proved inaccurate, leading to vaccine under- or over-estimation. Refresher training on adverse events and safe injection procedures was usually necessary.
Considerable experience in HPV vaccine delivery in LAMICs is available. Lessons are generally consistent across countries and dissemination of these could improve HPV vaccine introduction.
总结低收入和中等收入国家(LAMICs)人乳头瘤病毒(HPV)疫苗示范项目和国家计划的经验教训及成功的决定因素。
对56名关键信息提供者进行了访谈。通过系统的文献综述,从五个数据库中确定了2936篇摘要;筛选后纳入61篇全文。向国家代表征集了未发表的文献,包括评估报告;共收到188份文件。根据世界卫生组织新疫苗引入指南,制定了数据提取工具和访谈主题指南,概述了关键的调查领域。结果按主题进行了综合。
分析了46个国家的12个国家计划和66个示范项目的数据。在示范项目中,30个由佳达修®准入计划支持,20个由全球疫苗免疫联盟支持,4个由PATH支持,12个由其他方式支持。以学校为基础的疫苗接种辅以针对校外女孩的基于卫生机构的接种,实现了高覆盖率。关于仅在卫生机构接种策略的数据有限,对针对校外女孩的策略评估也很少。教师作为社会动员、同意、接种日协调、未完成接种者随访和不良事件随访的合作伙伴尽早参与,被认为非常宝贵。使用学校/机构登记册进行微观规划最有效地列举了目标人群;其他估计结果证明不准确,导致疫苗估计不足或过量。通常需要进行不良事件和安全注射程序的进修培训。
LAMICs在HPV疫苗接种方面有丰富的经验。各国的经验教训总体一致,传播这些经验教训可以改善HPV疫苗的引入。